DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Pregnancy Rates in IVF After Ovulation Triggering With Recombinant or Urinary Human Chorionic Gonadotrophin (HCG)

Information source: Universitair Ziekenhuis Brussel
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Embryonic Development; Pregnancy; VEGF

Intervention: 10000 IU urinary HCG (Drug); 250 mcg recombinant HCG (Drug)

Phase: Phase 3

Status: Active, not recruiting

Sponsored by: Universitair Ziekenhuis Brussel

Official(s) and/or principal investigator(s):
Paul Devroey, Professor, Study Director, Affiliation: Professor or OB-GYN


To access whether the ovulation triggering with rec-HCG instead urinary-HCG has any impact on the blastulation rate and pregnancy rate of patients undergoing IVF treatment

Clinical Details

Official title: Phase III Study on the Effects of Recombinant HCG Ovulation Triggering on Stimulation, Embryonic and Pregnancy Parameters in an IVF Program

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Primary outcome: blastulation rate

Secondary outcome: pregnancy rates, VEGF levels, OHSS rate


Minimum age: 20 Years. Maximum age: 36 Years. Gender(s): Female.


Inclusion Criteria:

- FSH<12,

- normal sperm,less than 36y,

- single blastocyst transfer

Exclusion Criteria:

- endometriosis stage 3&4,

- pco

Locations and Contacts

Centre for Reproductive Medicine, UZ Brussel, Brussels, Jette 1090, Belgium
Additional Information

main web page of the centre for reproductive medicine in UZ Brussels

Starting date: August 2005
Last updated: December 23, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017